ArticleThoracic cancer2018
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment.
Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors.Journal of neuro-oncology · 2025Article
- Article
- Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature.World journal of gastrointestinal oncology · 2025Article
- Spatial Multiomics Reveals Intratumoral Immune Heterogeneity with Distinct Cytokine Networks in Lung Cancer Brain Metastases.Cancer research communications · 2024Article
- Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2024Review
- Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab.Thoracic cancer · 2021Article
- Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.Cancers · 2021Review
- [Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).Journal of cancer research and clinical oncology · 2021Article
- Potentials of Non-InvasiveFrontiers in genetics · 2021Review
- Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.Frontiers in immunology · 2021Article
- Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.Journal of cancer research and clinical oncology · 2020Review
- Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.Neuro-oncology · 2020Review
- The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.Cancer biology & medicine · 2019Article
- [A Case of Pseudoprogression During Atezolizumab Therapy in Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has revolutionized the treatment of non-small cell lung cancer; however, its role in the treatment response of lung brain metastasis is unknown. Understanding immunotherapy activity in the central nervous system is important in order to avoid additional toxicity, such as that associated with the use of cerebral radiotherapy. We present two cases with clinical and radiological progression with increases in size and perilesional edema of brain lesions after treatment with a combination of ipilimumab and nivolumab. The increasing use of immunotherapy in lung cancer requires increased knowledge of new patterns of radiological response, such as pseudoprogression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.